Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Overview
  • Distribution
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

Strand Adds Corporate Thought Leader Ravi Venkatesan to its Board


News provided by

Strand Life Sciences

22 May, 2014, 10:30 IST

Share this article

Share toX

Share this article

Share toX

PR NEWSWIRE INDIA - Ravi Venkatesan joins Strand Life Sciences Board of Directors (PRNewsFoto/Strand Life Sciences)
PR NEWSWIRE INDIA - Ravi Venkatesan joins Strand Life Sciences Board of Directors (PRNewsFoto/Strand Life Sciences)

BANGALORE, May 22, 2014 /PRNewswire/ --

Ravi Venkatesan, the Chairman of Microsoft India from 2004-2011, who helped build and expand Microsoft's largest presence outside of the USA in India, has joined the Boards of Strand Life Sciences, a new generation healthcare innovation company headquartered in Bangalore, and its US subsidiary, Strand Genomics, Inc. Venkatesan is the author of the acclaimed "Conquering the Chaos: Win in India, Win Everywhere" published by HBR and currently the founder chairman of the Social Ventures Partners, India and serves as a director on the Boards of Infosys and AB Volvo.

     (Photo: http://photos.prnewswire.com/prnh/20140522/10098351)

Mr. Venkatesan has held multiple senior leadership positions. He served as the Chairman of Microsoft India from 2004-2011, and as the Chairman of Cummins India. He holds a BS in engineering from IIT Bombay, MS from Purdue University, and an MBA from Harvard Business School where he was a Baker Scholar. He was voted as the most influential MNC CEO by the Economic Times in 2011. He was also voted as one of India's best management thought leaders by Thinkers50.

"The advances in genomics are greatly complemented by those of computer science," said Ravi Venkatesan. "The future of cancer screening, diagnostics, and screening for genetic predispositions is being transformed by the melding of the two fields, and Strand Life Sciences is among the world leaders in this important transformative arena."

Commenting on his joining Strand's Board, Mr. Venkatesan, mentioned, "It is my pleasure to join the innovation leader in personalized medicine using genomics. In the past year, Strand has begun to commercialize its software platform and testing services for clinical use. It will play an increasingly important role going forward for India and the rest of the world."

Commenting on Mr. Venkatesan's joining the Board, Dr. Vijay Chandru, Chairman and CEO of Strand said, "We are delighted to have Ravi Venkatesan on board especially at a crucial junction when the company has strategized for exponential growth in the individualized medicine space. Ravi brings a wealth of experience that facilitates the company's growth as a global leader in clinical genomics."

About Strand Life Sciences

Founded in 2000, Strand Life Sciences is a leader in technology innovations for healthcare using genomics. Strand's entry into healthcare was through software products and services that combine advanced visualization, systems modeling, and scientific insights for enabling biological and health sciences research. Over 1400 institutions worldwide (about 30% of global market share) and patients at 100 hospitals benefit from Strand's technology products and services today, including several leading clinical research institutions, pharmaceutical and biotechnology companies. With a highly skilled workforce of over 200 computer and life scientists, Strand has set up three clinical and translational research laboratories in Bangalore that are enabled with cutting-edge Next Generation Sequencing (NGS) technologies. Strand is a portfolio company of Biomark Capital Partners, a San Francisco based global fund for health and life sciences. By enabling DNA sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise, Strand is bringing individualized medicine to the world.

For more information, visit www.strandls.com or follow us on twitter @StrandLife.

Media Contact: Preeti Goswami, [email protected], +919535678825, Ogilvy Public Relations

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.